Congenital brain tumours are rare. In general, they are preferentially located in the supratentorial compartment, and despite the occurrence of low-grade entities, these tumours are associated with a very poor prognosis. When strictly defined, the most common forms of congenital neoplasia are teratomas and astrocytomas. Among the astrocytomas, all grades (World Health Organization [WHO] I-IV) and many of the different subtypes are represented. This includes the most prognostically worrisome 'diffusely infiltrating' astrocytomas.
• focal neurologicsl deficit(s); and
• acute intracranial haemorrhage.
Although neuroimaging modalities are increasingly identifying cases during foetal development, aggressive surgical and chemo-/radiotherapeutic regimens have yet to significantly alter the dismal prognosis for most of these unfortunate patients. 5 As determined by Isaacs in his 2002 review, overall survival is only 28%. 2, 3 Numerous small case series and larger reviews have been published on the topic of early-onset paediatric brain tumours. 2, 3, [5] [6] [7] [8] [9] [10] [11] [12] [13] Ascertaining the frequency of individual congenital tumour types is often made difficult by the inclusion of older children in some analyses (up to 18 months of age in one study). [11] [12] [13] In particular, these latter studies often underestimate the frequency of teratomas. For example, in Larouche et al.'s review of 1,289 infants less than one year of age, astrocytomas accounted for 30.5% of the cases, while teratomas accounted for only 4.9% of the total. 11 Of the larger studies that were more strictly confined to the congenital time period, i.e. all cases less than or equal to two months of age, teratomas and astrocytomas were usually the most frequent tumour type. 2, 3, 5, 8 In Isaac's 2002 analysis of 225 congenital brain tumours, teratomas (44.9%) were by far the most frequent type, followed by astrocytomas (16%) and medulloblastomas (7.6%). glioblastomas and two anaplastic astrocytomas. 7 Similarly, in Lasky oligoastrocytoma (grade III), glioblastoma (grade IV) and anaplastic astrocytoma (grade III). 6 Based on these data, all grades (I-IV) of astrocytoma, and many of the different subtypes, appear to be represented in the congenital period; this includes very rare instances of gliosarcoma.
Gliosarcoma -What Can Be Learned from Adult Cases?
Gliosarcoma, WHO grade IV, is considered a variant of glioblastoma that exhibits not only elements of high-grade astrocytoma, but also areas of malignant mesenchymal differentiation, i.e. sarcoma.
Gliosarcomas comprise approximately 2-5% of all glioblastomas. [14] [15] [16] Despite their distinctive bi-phasic histology, gliosarcomas carry the same dismal prognosis as conventional glioblastomas.
In their study of 29 15 Moreover, gliosarcomas share a propensity for the supratentorial white matter of adults (mean patient age 52.1 years). 18 Notably, paediatric cases of gliosarcoma are uncommon and congenital cases of gliosarcoma are very rare. [19] [20] [21] Pathologically, the areas of high-grade astrocytoma and sarcoma in myofilaments. 21 The sarcomatous component of gliosarcoma may also take on the appearance of malignant fibrous histiocytoma, chondrosarcoma or osteosarcoma. 23 Rarely, epithelial areas may be seen, suggesting carciomatous differentiation. 24 The controversy regarding the histogenesis of gliosarcomas was largely resolved with the advent and implementation of modern genetic techniques. Given the distinct and often well circumscribed areas of glial and sarcomatous morphology, early pathological accounts proposed the gliosarcomas represented a 'collision' tumour,
i.e. two separate neoplasms. 18 Moreover, the sarcomatous element was felt by some authors to arise from regions of proliferative vascular mesenchyma, i.e. microvascular proliferation.
25,26
The collision tumour hypothesis of gliosarcomas has since been abandoned in favour of a monoclonal histogenesis wherein the sarcomatous element is derived through either metaplasia or 'dedifferentiation' of the glial component. 
Congenital Gliosarcoma -A Rare Entity
Only Figure 1D ) contained prominent nucleoli. 32 Unfortunately, surgical, treatment and follow-up details were not described.
Chadduck et al. published a subsequent instance of congenital gliosarcoma in a two-month-old female whose mother was exposed to the insecticide heptachlor via ingested dairy milk during pregnancy. 34 This girl presented with projectile vomiting at two weeks of age and had steadily increasing macrocephaly. CT scanning revealed an enhancing lesion involving most of the right hemisphere, plus secondary hydrocephalus. Pathological details (reviewed by the renowned Dr L Rubinstein) were limited, but described spindled fibrosarcomatous-like
Head and Neck Cancer In the most detailed clinicopathological report to date, Hochwald et al. Cases pertinent to the above differential diagnosis, and not previously recognised to be gliosarcomas, are also present in the literature.
Among the eight original cases of so-called 'sarcoglioma' described by Lalitha and Rubinstein, three cases contained histological foci consistent with glioblastoma and fibrosarcoma; in particular, one of these three occurred in a 2.5-month-old male. 39 Although the concept of a secondary glioma arising out of a primary intracranial sarcoma is intriguing (i.e. sarcoma with low-grade glioma), its utility becomes moot in those cases with dual malignant features, i.e. sarcoma and glioblastoma, since it would be extremely difficult to determine which component was primary. Glioblastoma is exceedingly more common than primary intracranial sarcoma. Since
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Conclusion
Clearly, in-depth analysis of future cases of congenital gliosarcoma is required. Detailed pathological, genetic and treatment data are needed, especially given the encouraging results of Brat et al., which suggest that congenital glioblastomas are not only genetically different from their adult counterparts, but are also prognostically different given the extended survival seen in a subset of their patients (three patients with survival at or beyond 5.5 years). 1 Hopefully, novel data will pave the road to an effective treatment for these unfortunate children. n
